
STAA
STAAR Surgical CompanyNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.91
P/S
4.18
EV/EBITDA
-23.64
DCF Value
$1.12
FCF Yield
-4.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.6%
Operating Margin
-33.3%
Net Margin
-33.6%
ROE
-23.2%
ROA
-18.7%
ROIC
-19.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $57.8M | $-18.3M | $-0.36 |
| FY 2025 | $239.4M | $-80.4M | $-1.62 |
| Q3 2025 | $94.7M | $8.9M | $0.18 |
| Q2 2025 | $44.3M | $-16.8M | $-0.34 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.04
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.